JPS6097914A - Enema - Google Patents

Enema

Info

Publication number
JPS6097914A
JPS6097914A JP20585883A JP20585883A JPS6097914A JP S6097914 A JPS6097914 A JP S6097914A JP 20585883 A JP20585883 A JP 20585883A JP 20585883 A JP20585883 A JP 20585883A JP S6097914 A JPS6097914 A JP S6097914A
Authority
JP
Japan
Prior art keywords
enema
sodium citrate
glycerin
purified water
main component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP20585883A
Other languages
Japanese (ja)
Other versions
JPS632532B2 (en
Inventor
Izumi Hagiwara
泉 萩原
Takayuki Nishikawa
西川 隆行
Yutaka Amou
天羽生 豊
Tomohiko Koshibe
越部 智彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sato Pharmaceutical Co Ltd
Original Assignee
Sato Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sato Pharmaceutical Co Ltd filed Critical Sato Pharmaceutical Co Ltd
Priority to JP20585883A priority Critical patent/JPS6097914A/en
Publication of JPS6097914A publication Critical patent/JPS6097914A/en
Publication of JPS632532B2 publication Critical patent/JPS632532B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PURPOSE:An enema having physical and chemical stability, having the same effect as that of glycerin enema, and low side effect such as a stomachache, etc., containing sodium citrate as a main component. CONSTITUTION:An enema containing sodium citrate, preferably trisodium citrate hydrate as a main component. An amount of it blended is preferably 10- 30wt%. An aqueous solution of sodium citrate is found to have the same effect as that of glycerin, and a few clinical demerits glycerin has. Namely, it has no side effect such as a stomachache, and there is sufficient time to open the bowels. The enema is an extremely useful enema which is inexpensive, easily handeable, and has improved long-term safety.

Description

【発明の詳細な説明】 本発明はクエン酸す) IJウムを主成分として含有す
る浣腸剤に関するものである。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an enema containing citric acid (IJ) as a main component.

従来、浣腸剤としてはグリセリン液、石ケン液などがあ
るが、実際にはグリセリン浣腸剤がそのほとんどである
。しかしながら、グリセリン浣腸はグリセリンによる直
腸粘膜への刺激により、大腸の樗動を誘起させるという
作用機序の特質上、腹痛などの副作用を伴なうことが欠
点としてあげられている。
Conventionally, enema preparations include glycerin solutions and soap solutions, but in reality most of them are glycerin enema preparations. However, glycerin enemas have a disadvantage in that they are accompanied by side effects such as abdominal pain due to their mechanism of action, which is to stimulate the rectal mucosa with glycerin, thereby inducing peristalsis of the large intestine.

本発明者らは上記の如き欠点を排除した新規な浣腸剤の
開発を意図して種々の検討を行なった結果、クエン酸ナ
トリウム水溶液がグリセリンと同等の効果を有するとと
もに、上記の如き欠点が少ないことを見出し、本発明を
完成させるにいたった。
The present inventors conducted various studies with the intention of developing a new enema that eliminates the above-mentioned drawbacks, and as a result, we found that an aqueous sodium citrate solution has an effect equivalent to that of glycerin, and has fewer of the above-mentioned drawbacks. This discovery led to the completion of the present invention.

本発明について以下に詳細に述べる。The present invention will be described in detail below.

本発明において用いられるクエン酸ナトリウムは一般式
Na5C6H,02・nH,、o(n−=o、2+:L
s)、Na2 HC6H507・nH2O(n=0.1
.2)、NaH2C6H,07・nH2O(n=0.1
)で表わされるものであり、なかでもクエン酸三ナトリ
ウム・三水塩が望ましく用いられる。
Sodium citrate used in the present invention has the general formula Na5C6H,02·nH,, o(n-=o, 2+:L
s), Na2 HC6H507・nH2O (n=0.1
.. 2), NaH2C6H,07・nH2O (n=0.1
), among which trisodium citrate trihydrate is preferably used.

クエン酸ナトリウムの配合量は5〜50%が望ましく、
更には10〜30チが望ましい。
The blending amount of sodium citrate is preferably 5 to 50%.
Furthermore, 10 to 30 inches is desirable.

本発明における浣腸剤はクエン酸ナトリウムの水溶液で
あるが、これに各種の添加剤を加えることは勿論可能で
ある。例えば防腐剤として安息香酸類、パラベン類ある
いはソルビン酸など、粘稠化剤としてCMC−Na、キ
ドロキシブロピルセルロース、カルボキシビニルポリマ
ーなどの高分子増粘剤、キサンタンガム、カラギーナン
、ローカストビーンガムなどの天然ガム質、ソルビトー
ル、マンニトールなどの糖類、プロピレングリコール、
1.3−ブチレングリコール、ポリエチレングリコール
などの多価アルコール類などを用いることが可能である
Although the enema in the present invention is an aqueous solution of sodium citrate, it is of course possible to add various additives to it. For example, preservatives such as benzoic acids, parabens, or sorbic acid, thickening agents such as CMC-Na, hydroxypropylcellulose, carboxyvinyl polymer, and other polymer thickeners, xanthan gum, carrageenan, locust bean gum, and other natural agents. Gummy substances, sugars such as sorbitol and mannitol, propylene glycol,
It is possible to use polyhydric alcohols such as 1.3-butylene glycol and polyethylene glycol.

また、場合によっては効果を増強させるために、少量の
グリセリンなど他の浣腸剤に用いられる成分を添加する
ことも可能である。
In some cases, it is also possible to add small amounts of ingredients used in other enema preparations, such as glycerin, to enhance the effect.

本発明における浣腸剤の製造方法は、所要量のクエン酸
ナトリウムを秤取し、精製水を加えて溶解し、所定の濃
度に調製する。
In the method for producing an enema according to the present invention, a required amount of sodium citrate is weighed out, and purified water is added to dissolve it to obtain a predetermined concentration.

以下に試験例をあげ、更に具体的に説明するが、本発明
は以下の試験例により何ら限定されるものではない。
Test examples will be given below to provide a more specific explanation, but the present invention is not limited by the following test examples.

試験例 (製剤例A) クエン酸二ナトリウム・三水塩 100f!−精製水で
全量 1.000m/! クエン酸ナトリウム・三水塩10ozを秤取し、これに
精製水を加えて攪拌溶解したのち、精製水を加えて全量
1.000 mlとする。
Test example (Formulation example A) Disodium citrate trihydrate 100f! - Total amount of purified water 1.000m/! Weigh out 10 oz of sodium citrate trihydrate, add purified water to it, stir and dissolve, and then add purified water to make a total volume of 1.000 ml.

(製剤例B) クエン酸三ナトリウム・三水塩 200p精製水で全量
 1.OOOmj クエン酸クエン酸ナトリウム20ofを秤取し、これに
精製水を加えて攪拌溶解したのち、精製水を加えて全量
1,000m#とする。
(Formulation Example B) Trisodium citrate trihydrate Total amount with 200p purified water 1. OOOmj Citric acid Weigh out 20 of sodium citrate, add purified water to it, stir and dissolve, and then add purified water to make a total amount of 1,000 m#.

(製剤例C) クエン酸三ナトリウム・三水塩 2001ソルビン酸 
500〜 精製水で全量 1.000前 クエン酸三ナトリウム・三水塩200y−を秤取し、こ
れに温精製水(40〜50℃)を加えて攪拌溶解したの
ち、ソルビン酸500■を加えて攪拌溶解し、精製水を
加えて全量1.ooomzとする。
(Formulation Example C) Trisodium citrate trihydrate 2001 sorbic acid
500 - Weigh out 200 y of trisodium citrate trihydrate (total volume 1,000 with purified water), add warm purified water (40 to 50°C) and dissolve with stirring, then add 500 ml of sorbic acid. Stir to dissolve and add purified water to bring the total volume to 1. ooomz.

(製剤例D) クエン酸三ナトリウム・三水塩 400ii1−ソルビ
ン酸 500m9 精製水で全量 1.000mJ クエン酸クエン酸ナトリウム4009−を秤取し、これ
に温精製水(40〜50°C)を加えて攪拌溶解したの
ち、ソルビン酸500■を加えて攪拌溶解し、精製水を
加えて全量1.000 mAとする。
(Formulation Example D) Trisodium citrate trihydrate 400ii1-Sorbic acid 500m9 Total volume with purified water 1.000mJ Weigh out citric acid sodium citrate 4009-, and add hot purified water (40-50°C) to it. After stirring and dissolving, add 500 μl of sorbic acid, stir and dissolve, and add purified water to make a total volume of 1.000 mA.

このようにして製剤したクエン酸ナトリウム浣腸剤につ
いて、臨床効果をグリセリン浣腸剤と比較した。
The clinical efficacy of the sodium citrate enema thus formulated was compared with that of the glycerin enema.

試験は二重盲検法により実施した。クエン酸ナトリウム
浣腸剤は製剤例A、B、C及びDにより効果が同等であ
ったので、製剤例Cすなわち20チクエン酸ナトリウム
浣腸剤を被検薬とした。対照薬は50%グリセリン浣腸
剤とし、投与量はともに6omiとした。試験対象者は
産婦人科の患者で、3日以上の便秘の患者もしくは術前
の浣腸処理を必要とする患者とし、妊婦は除外した。
The study was conducted in a double-blind manner. Since the effects of sodium citrate enema were equivalent among Formulation Examples A, B, C, and D, Formulation Example C, that is, 20% sodium citrate enema, was used as the test drug. The control drug was a 50% glycerin enema, and both doses were 6omi. The test subjects were obstetrics and gynecology patients who had constipation for three days or more or required preoperative enema treatment, and pregnant women were excluded.

結果を以下に示す。The results are shown below.

クエン酸ナトリウム 7.9分 グリセリン 5.7分 (副作用) (有用性) 結果について考察すると、効果については快適およびや
や快適に排便できたものが、クエン酸ナトリウムで19
例、グリセリンで20例という結果で、それぞれ全体の
79.2 %および83.3 %で、両者の間に効果の
差は認められなかった。なお、悪化例がグリセリンに2
例認められた。
Sodium citrate 7.9 minutes Glycerin 5.7 minutes (side effects) (Usefulness) Looking at the results, we found that sodium citrate was able to defecate comfortably and somewhat comfortably;
For example, in 20 cases of glycerin, the results were 79.2% and 83.3% of the total, respectively, and no difference in effectiveness was observed between the two. In addition, there are two cases of worsening when glycerin is used.
Examples were recognized.

排便までに要す時間はクエン酸ナトリウム7.9分、グ
リセリン5.7分であった。
The time required for defecation was 7.9 minutes for sodium citrate and 5.7 minutes for glycerin.

副作用については、腹痛を感じたものがクエン酸ナトリ
ウムで2例、グリセリンで7例と、クエン酸す) IJ
ウムの方が少ない傾向にあった。局所刺激はともに認め
られなかった。
As for side effects, abdominal pain was felt in 2 cases with sodium citrate and 7 cases with glycerin (citric acid).
Umu tended to have fewer cases. No local irritation was observed in either case.

有用性の総合判定は、やや有用以上がクエン酸ナトリウ
ムで19例、グリセリンで20例で、それぞれ79.2
 %および83.3 %に相当し、両者の間に有用性の
差は認められなかった。
The overall evaluation of usefulness was 79.2 for sodium citrate in 19 cases and glycerin in 20 cases, respectively.
% and 83.3%, and no difference in usefulness was observed between the two.

以上述べたように臨床試験の結果からクエン酸ナトリウ
ム浣腸剤は従来のグリセリン浣腸剤と同等の効果および
有用性を有しており、実際の臨床使用上、何ら支障をま
ねくものではない。浣腸剤の有用性の評価としていくつ
かの条件があるが、患者側の条件として従来のグリセリ
ン浣腸剤に見られた腹痛は最も大きな問題であった。特
に妊婦など切迫流産の可能性のある者に対しては、この
問題は重要である。本臨床実験から明らかなように、ク
エン酸ナトリウム浣腸剤は、この点の改善を充分溝たし
ている。さらに、排便時間がやや長くなっている点につ
いても有用性がある。すなわち、病院等で浣腸を行った
場合、看護婦または付き添い人が処置し、患者はその後
トイレに行くことにより、多少の時間的余裕が必要であ
るが、グリセリン浣腸は便意が早くきすぎる為、この点
の改善を指摘されていた。この点についてもクエン酸ナ
トリウム浣腸は改善していると言える。
As mentioned above, the results of the clinical trials show that the sodium citrate enema has the same effect and usefulness as the conventional glycerin enema, and does not pose any problem in actual clinical use. There are several conditions for evaluating the usefulness of enemas, but the most significant problem for patients was abdominal pain, which was seen with conventional glycerin enemas. This issue is particularly important for pregnant women and others who are at risk of threatened miscarriage. As is clear from the present clinical experiment, the sodium citrate enema is sufficient to improve this point. Furthermore, the fact that defecation time is slightly longer is also useful. In other words, when an enema is administered in a hospital, etc., a nurse or an attendant administers the procedure, and the patient then needs some time to go to the toilet, but with glycerin enemas, the urge to defecate occurs too quickly. Improvements in this point were pointed out. It can be said that sodium citrate enema is an improvement in this respect as well.

さらにクエン酸ナトリウムはグリセリンに比較して安価
であり、クエン酸ナトリウム水溶液は粘度がない為、極
めて扱い易い。このことは臨床使用時にも有用である。
Furthermore, sodium citrate is cheaper than glycerin, and an aqueous solution of sodium citrate has no viscosity, so it is extremely easy to handle. This is also useful during clinical use.

また、クエン酸ナトリウム浣腸は長期安全性にすぐれて
いる。以上よりクエン酸ナトリウム浣腸剤は従来のグリ
セリン浣腸剤4゛°′ を有していた臨床的欠点を克服し、同等の効果を有し、
物理化学的にも安定な極めて有用な浣腸剤である。
Additionally, sodium citrate enemas have excellent long-term safety. From the above, the sodium citrate enema overcomes the clinical drawbacks of the conventional glycerin enema 4゛°' and has the same effect.
It is an extremely useful enema agent that is physicochemically stable.

特許出願人 佐藤製薬株式会社 代理人弁理士 1) 代 蒸 治 手続補正書(方式) %式% 1、事件の表示 特願昭58−205858号 2 発明の名称 浣 腸 剤 3、補正をする者 事件との関係 特許出願人 名称 佐藤製薬株式会社 4、代理人 〒103 住 所 東京都中央区八重洲1丁目9番9号東京建物ビ
ル(電話271−8508代表)5、補正命令の日付 昭和59年1月11日(59弓・31発送)6、補正の
対象 明 細 書 7、補正の内容 明細書の浄書(内容に変更なし)
Patent Applicant Sato Pharmaceutical Co., Ltd. Representative Patent Attorney 1) Representative Amended Procedures for Vaporization (Method) % Formula % 1. Indication of the Case Patent Application No. 1982-205858 2. Name of the Invention Enema 3. Person making the amendment Relationship to the case Name of patent applicant: Sato Pharmaceutical Co., Ltd. 4, Agent: 103 Address: Tokyo Tatemono Building, 1-9-9 Yaesu, Chuo-ku, Tokyo (Telephone: 271-8508) Date of amendment order: 1982 January 11th (59 bows, 31 shipments) 6. Statement of the subject of amendment 7. Engraving of the statement of contents of the amendment (no change in content)

Claims (2)

【特許請求の範囲】[Claims] (1)クエン酸ナトリウムを主成分として含有すること
を特徴とする浣腸剤。
(1) An enema characterized by containing sodium citrate as a main component.
(2)クエン酸ナトリウムがクエン酸三ナトリウム・三
水塩である特許請求の範囲(1)記載の浣腸剤。
(2) The enema according to claim (1), wherein the sodium citrate is trisodium citrate trihydrate.
JP20585883A 1983-11-04 1983-11-04 Enema Granted JPS6097914A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP20585883A JPS6097914A (en) 1983-11-04 1983-11-04 Enema

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20585883A JPS6097914A (en) 1983-11-04 1983-11-04 Enema

Publications (2)

Publication Number Publication Date
JPS6097914A true JPS6097914A (en) 1985-05-31
JPS632532B2 JPS632532B2 (en) 1988-01-19

Family

ID=16513875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP20585883A Granted JPS6097914A (en) 1983-11-04 1983-11-04 Enema

Country Status (1)

Country Link
JP (1) JPS6097914A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002285665A (en) * 2001-03-23 2002-10-03 Okamura Corp Partition panel structure

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002285665A (en) * 2001-03-23 2002-10-03 Okamura Corp Partition panel structure

Also Published As

Publication number Publication date
JPS632532B2 (en) 1988-01-19

Similar Documents

Publication Publication Date Title
Nicholls et al. Effect of oestrogen therapy on plasma and urinary levels of uric acid
JP2774106B2 (en) Laxative aqueous solution
JP5177446B2 (en) Compositions composed of low viscosity glycosaminoglycans and their use in the treatment of interstitial cystitis
ES2655172T3 (en) Procedure for temporary preparation of a colonoscopy in which a picosulfate composition is administered
Dolman et al. The effect of aldosterone and the renin‐angiotensin system on sodium, potassium and chloride transport by proximal and distal rat colon in vivo.
Loveman Experimental aspect of fixed eruption due to alurate, a compound of allonal
GARB et al. Mycosis fungoides with bullous lesions: report of a case resistant to roentgen and arsenical therapy; effects of empiric therapy, partly based on laboratory investigations
Cole Historical features of cholecystography: the Carman Lecture
JPS6097914A (en) Enema
Beck Toxic effects from bismuth subnitrate: with reports of cases to date
Schmelzer et al. Colonic cleansing, fluid absorption, and discomfort following tap water and soapsuds enemas
Caraway Pentothal Sodium With Nasal Oxygen: A Report of 3810 Consecutive Cases.
Bass UNCINARIASIS IN MISSISSIPPI.
Mengoli Excerpts from the history of postoperative fluid therapy
Shay et al. A gastric mucigogue action of the alkyl sulfates
KR20230140488A (en) A composition for bowel cleansing
King et al. The effect of atropine sulfate, morphine sulfate, pilocarpine hydrochloride, prostigmine methylsulfate, sodium salt of dehydrocholic acid and secretin on the gastric and duodenal secretions of normal persons when fasting
Moore Management of syphilis in general practice
Curtis et al. The effect of certain hemostatic agents and the local use of diluted epinephrine on bleeding during oral surgical procedures
SWARTZ Drug Formus: NuLYTELY (PEG 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution)
Turner et al. Fulminating Meningococcal Septicaemia
MacPherson et al. Case of Solitary Tuberculous Ulcer of the Lip
France Pains of the Female Pelvis: Their Diagnostic Significance and Treatment
Tracy A Bit of Hormonology, with Practical Applications
Whitwell Behcet's Syndrome